Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

Core Insights - Catalyst Pharmaceuticals is showcasing real-world findings in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference, emphasizing their commitment to advancing research and patient care [1][2] Poster Presentations - The company will present multiple posters focusing on the real-world analysis of vamorolone, a novel corticosteroid, in DMD patients, including studies on cardiac medication use and glucocorticoid treatment duration [3][4] - Specific poster titles include "Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy" and "Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy" [3][4] Symposium - Catalyst Pharmaceuticals is sponsoring an MDA Industry Forum in conjunction with Santhera Pharmaceuticals, which will feature insights from clinical leaders on advancing understanding of DMD [5][6] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a strong commitment to patient care and accessibility [6] - The company has been recognized by Forbes as one of America's Most Successful Companies for three consecutive years (2023-2025) and listed on the 2025 Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies [6]